Targeted therapy in BRAF-mutant melanoma: Advances and challenges (Review)
Lu Zhang, Dongliang Shen, Jianguo Feng, Liling Tang · 2026
Read Targeted therapy in BRAF-mutant melanoma: Advances and challenges (Review) by Lu Zhang, Dongliang Shen, Jianguo Feng, Liling Tang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13344363.txt.
Description
Lu Zhang and colleagues reviewed in 2026 the rise, success, and limits of targeted drugs for melanoma carrying a BRAF gene change. More than half of melanomas carry this change, which switches on a growth pathway and drives rapid cell division, making it a natural drug target.
The review traces BRAF blockers and MEK blockers, which act further down the same pathway, from discovery through approval and clinical use. Both drug classes first shrink tumours, yet nearly all patients later develop resistance and relapse, at the original site and elsewhere. By mapping how tumours escape these drugs, the authors point to where new combinations and strategies must focus if lasting control is to replace short-lived gains.
Catalog record
| CREATOR | Lu Zhang, Dongliang Shen, Jianguo Feng, Liling Tang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |